Diabetes medicines beyond blood sugar: understanding heart and kidney benefits
About this article: AI-assisted, not independently clinically reviewed
Prepared with AI-assisted research using the sources below. Not independently reviewed by a clinician. Guidance and individual circumstances can change; use this article to prepare for a clinical conversation, not to choose treatment.
Sources checked 2026-09-05. Last updated 2026-09-05.
The short version
- Some medicines have demonstrated benefits beyond lowering glucose.
- Benefits depend on the particular medicine, outcome and patient population.
- A treatment plan needs side-effect, illness, fasting and surgery instructions.
'My HbA1c is already good. Why are we discussing another diabetes medicine?' Sometimes the answer is that the treatment decision is about heart or kidney outcomes as well as glucose. Understanding the intended purpose makes it easier to weigh the potential benefit against side effects, monitoring and cost.
The treatment goal may be broader than HbA1c
The ADA's 2026 standards recommend an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated cardiovascular benefit for appropriate people with type 2 diabetes and established atherosclerotic disease or chronic kidney disease, as part of comprehensive care. The wording 'with demonstrated benefit' matters: evidence for one drug and one outcome should not automatically be assigned to every product in a class.
Evidence: ADA Standards of Care 2026, chapter 10: cardiovascular disease and risk management
The standards also describe organ-protective treatment decisions in selected patients irrespective of HbA1c. That does not make glucose monitoring irrelevant. Kidney function, heart failure, existing cardiovascular disease, weight, tolerability, hypoglycaemia risk and other medicines all contribute to the choice. These recommendations concern defined clinical situations, not a general instruction for anyone worried about future heart disease.
Evidence: ADA Standards of Care 2026, chapter 9: pharmacological treatment
Read a trial's population before its headline
SELECT studied semaglutide in 17,604 adults aged at least 45 with overweight or obesity and established cardiovascular disease, but without diabetes. Over a mean 39.8 months, cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 6.5% with semaglutide and 8.0% with placebo. That is a 1.5 percentage-point absolute difference in that population, alongside a hazard ratio of 0.80.
Evidence: Lincoff et al., NEJM 2023: SELECT cardiovascular outcomes trial
The trial shows that benefits can extend beyond glucose lowering, but it was not a study of low-risk young adults or everyone seeking weight loss. Adverse events led to permanent treatment discontinuation in 16.6% versus 8.2%. A headline quoting a relative reduction without the starting risk, follow-up or tolerability leaves out information needed for a fair decision.
Evidence: Lincoff et al., NEJM 2023: SELECT cardiovascular outcomes trial
Safety needs a written plan
SGLT2 medicines require attention to hydration, genital or urinary symptoms and uncommon but serious ketoacidosis. Empagliflozin's patient information warns that nausea, vomiting, abdominal pain, unusual tiredness or breathing difficulty may signal ketoacidosis even without very high glucose. For suspected ketoacidosis, stop empagliflozin and seek immediate medical advice or emergency care, as the medicine guidance directs. Do not wait for a high glucose number to take serious symptoms seriously.
Evidence: MedlinePlus 2025: empagliflozin precautions and serious symptoms
Ask the prescriber for instructions before surgery, prolonged fasting or an illness that prevents normal eating and drinking. Those circumstances may require a temporary change, but a blog cannot provide a safe personalised stop-and-restart schedule. Tell the team about pregnancy plans or breastfeeding, and include all medicines and supplements in the review.
Evidence: MedlinePlus 2025: empagliflozin precautions and serious symptoms
GLP-1 medicines can cause gastrointestinal side effects. Semaglutide information highlights nausea, vomiting, diarrhoea and dehydration concerns, among other precautions. Severe or persistent symptoms need clinical advice. Tolerability, the specific preparation and your medical history matter; changing doses or borrowing somebody else's product is not a safe way to test whether it suits you.
Five questions before starting
- Which outcome are we targeting: glucose, kidney progression, heart failure, cardiovascular events, weight or several together?
- Which study population is closest to me, and what absolute benefit is realistic?
- What monitoring is needed, and could another medicine need adjustment?
- What should I do during vomiting, poor intake, Ramadan fasting or a planned procedure?
- What are the expected cost and local availability, and what alternative exists if I cannot tolerate or afford it?
Record the reason for treatment beside the medicine name, not just the dose. That makes future reviews clearer and helps prevent a helpful therapy being mistaken for an unnecessary duplicate. Keep broader prevention in the plan too: these medicines do not replace blood-pressure care, lipid management or avoiding tobacco.
Evidence: ADA Standards of Care 2026, chapter 10: cardiovascular disease and risk management
This article is educational and is not medical advice, a diagnosis, or a treatment recommendation. CardioTrack is not intended for diagnosis or treatment. Always discuss your own results with a qualified clinician.
Sources and further reading
- ADA Standards of Care 2026, chapter 10: cardiovascular disease and risk management
- ADA Standards of Care 2026, chapter 9: pharmacological treatment
- Lincoff et al., NEJM 2023: SELECT cardiovascular outcomes trial
- MedlinePlus 2025: empagliflozin precautions and serious symptoms
- MedlinePlus: semaglutide medicine information